natgillin/translations-raw huggingface dataset:
A slow increase of the dose may also improve gastrointestinal tolerability.
Prenašanje zdravila v prebavilih je možno izboljšati tudi s počasnim povečevanjem odmerka.
A slower administration is preferable in patients who react to the treatment with “flu-like” symptoms (see section 4.8).
Pri bolnikih, ki se na zdravljenje odzovejo z gripi podobnimi simptomi, je zaželeno počasnejše dajanje (glejte poglavje 4.8).
A slower terminal elimination phase follows with a dose-independent mean terminal elimination half- life of 2 to 3 h.
Sledi počasnejša faza terminalne eliminacije, ki ima od odmerka neodvisen povprečen razpolovni čas terminalne eliminacije od 2 do 3 ure.
a slowing of the rate of growth of children and adolescents an effect on the adrenal gland (a small gland next to the kidney)
upočasnjena rast pri otrocih in mladostnikih, vpliv na nadledvično žlezo (majhna žleza nad ledvico).
A small (n = 83), Phase II, randomised, double-blind study in patients receiving chemotherapy for de novo acute myeloid leukaemia compared pegfilgrastim (single dose of 6 mg) with filgrastim, administered during induction chemotherapy.
Majhna (n = 83) randomizirana, dvojno slepa študija II. faze pri bolnikih, ki so dobivali kemoterapijo zaradi de novo akutne mieloične levkemije, je primerjala pegfilgrastim (enkraten odmerek 6 mg) s filgrastimom ob aplikaciji med indukcijsko kemoterapijo.
A small (n=83), Phase II, randomised, double-blind study in patients receiving chemotherapy for de novo acute myeloid leukaemia compared pegfilgrastim (single dose of 6 mg) with filgrastim, administered during induction chemotherapy.
Majhna (n = 83) randomizirana, dvojno slepa študija II. faze pri bolnikih, ki so dobivali kemoterapijo zaradi de novo akutne mieloične levkemije, je primerjala pegfilgrastim (enkraten odmerek 6 mg) s filgrastimom ob aplikaciji med indukcijsko kemoterapijo.
A small air bubble is normal.
Majhen zračni mehurček je običajen.
A small air bubble may remain in the pre-filled pen – this is normal.
V napolnjenem injekcijskem peresniku lahko ostane majhen zračni mehurček – to je normalno.
A small air bubble will not affect your dose and you can continue to take your dose as usual.
Majhen mehurček ne bo vplival na vaš odmerek, zato lahko odmerek kot običajno injicirate naprej.
A small amount of bleeding may occur.
Na vbodnem mestu lahko pride do manjše krvavitve.
A small amount of crystals does not affect the strength or safety of your child’s medicine.
Če je kristalov malo, ne vplivajo na jakost ali varnost otrokovega zdravila.
A small amount of excess product will remain in the vial.
V viali bo ostala majhna količina preostalega zdravila.
A small amount of orally administered oxybutynin is excreted in the mother’s milk.
Majhna količina peroralno uporabljenega oksibutinina se izloča v materino mleko.
A small amount of pravastatin is excreted in human breast milk; therefore pravastatin is contraindicated during breastfeeding (see section 4.3).
Pravastatin se v majhnih količinah izloča v materino mleko, zato je med dojenjem kontraindiciran (glejte poglavje 4.3).
A small amount of residual solvent will remain in the vial following withdrawal.
Po tem bo v viali ostala majhna količina preostalega vehikla.
A small amount of the ingredients in Lamivudine/Zidovudine Teva can also pass into your breast- milk.
Majhna količina sestavin zdravila Lamivudin/zidovudin Teva lahko prehaja v materino mleko.
A small but higher number of bladder, breast and prostate cancer cases were seen in patients who took Edistride compared with patients who took placebo.
Majhno, vendar višje število primerov raka mehurja, dojke in prostate so zabeležili pri bolnikih, ki so jemali zdravilo Edistride, v primerjavi z bolniki, ki so jemali placebo.
A small but higher number of bladder, breast and prostate cancer cases were seen in patients who took Forxiga compared with patients who took placebo.
Majhno, vendar višje število primerov raka mehurja, dojke in prostate so zabeležili pri bolnikih, ki so jemali zdravilo Forxiga, v primerjavi z bolniki, ki so jemali placebo.
A small but statistically significant difference in CFS improvement was observed between the treatment groups at Month 6 in favour of IKERVIS (mean change from baseline in CFS -1.05 with IKERVIS and -0.82 with vehicle, p=0.009).
Majhno, a statistično značilno razliko v izboljšanju CFS med skupinama zdravljenja so v 6. mesecu opazili v korist zdravila IKERVIS (povprečna sprememba CFS od izhodišča -1,05 za zdravilo IKERVIS in -0,82 za vehikel, p = 0,009).
A small clinical study was conducted to evaluate the safety, antiviral activity and pharmacokinetics of tenofovir disoproxil fumarate in combination with emtricitabine in HIV infected patients with renal impairment.
Izvedena je bila majhna klinična študija za ocenitev varnosti, protivirusne aktivnosti in farmakokinetike dizoproksiltenofovirijevega fumarata v kombinaciji z emtricitabinom pri bolnikih, okuženih z virusom HIV z ledvično okvaro.
A small decrease in trametinib bioavailability, corresponding to a decrease in AUC of 12%, was estimated when trametinib is administered in combination with dabrafenib, a CYP3A4 inducer, using a population PK analysis.
Po podatkih populacijske farmakokinetične analize so ocenili, da pri odmerjanju trametiniba v kombinaciji z dabrafenibom, ki je induktor CYP3A4, pride do majhnega zmanjšanja biološke uporabnosti trametiniba, ki se ujema z zmanjšanjem njegove AUC za 12 %.
A small dose of another medicine, ritonavir, is normally given at the same time as a ‘booster’.
Hkrati se običajno daje majhen odmerek drugega zdravila, ritonavirja, kot „stopnjevalca“.
A small number of cases of hepatitis-B reactivation, some with fatal outcome, have been reported in granulomatosis with polyangiitis and microscopic polyangiitis patients receiving MabThera in the postmarketing setting.
Pri bolnikih z granulomatozo s poliangiitisom in mikroskopskim poliangiitisom, ki so zdravilo MabThera prejemali v obdobju trženja, so poročali o majhnem številu primerov reaktivacije hepatitisa B; nekateri od teh primerov so se končali s smrtjo.
A small number of growth hormones deficient patients treated with growth hormone have had leukaemia (blood cancer).
Pri manjšem številu bolnikov s pomanjkanjem rastnega hormona, ki so se zdravili z rastnim hormonom, so poročali o pojavu levkemije (krvnega raka).
A small number of hepatically impaired patients (serum bilirubin between 1.5 and 10 mg/dl) were given intravenous topotecan at 1.5 mg/m2 for five days every three weeks.
Le manjše število bolnikov z jetrno okvaro (vrednost serumskega bilirubina med 1,5 in 10 mg/dl) je prejelo intravenski odmerek 1,5 mg/m2 po pet dni na vsake tri tedne.
A small number of hepatically impaired patients (serum bilirubin between 1.5 and 10 mg/dl) were given intravenous topotecan at 1.5 mg/m2 for five days every three weeks.
Majhno število bolnikov z jetrno okvaro (vrednost bilirubina v serumu med 1,5 in 10 mg/dl) je prejemalo intravensko odmerek topotekana 1,5 mg/m2 po pet dni na vsake tri tedne.
A small number of hepatically impaired patients (serum bilirubin between 1.5 and 10 mg/dl) were given intravenous topotecan at 1.5 mg/m2 for five days every three weeks.
Majhno število bolnikov z okvaro jeter (koncentracija bilirubina v serumu med 1,5 in 10 mg/dl) je dobivalo intravenski topotekan v odmerku 1,5 mg/m2 pet dni vsake tri tedne.
A small number of patients have experienced hair loss at the treatment site or surrounding area.
Pri manjšem številu bolnikov je prišlo do izpadanja las na zdravljenem predelu ali v njegovi okolici.
A small number of people being treated with anti- epileptics such as Zonegran have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Zonegran, so se pojavile misli o samopoškodovanju ali samomoru.
A small number of people being treated with anti- epileptics such as Zonisamide Mylan have had thoughts of harming or killing themselves
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki kot je zdravilo Zonisamid Mylan, so se pojavile misli o samopoškodovanju ali samomoru;
A small number of people being treated with anti-epileptics have had thoughts of harming or killing themselves.
Majhno število oseb, ki se je zdravilo z antiepileptiki, je imelo misli o samopoškodovanju ali samomoru.
A small number of people being treated with anti-epileptics such as lacosamide have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je lakozamid, so se pojavile misli na samopoškodovanje ali samomor.
A small number of people being treated with anti-epileptics such as Lyrica have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Lyrica, so se pojavile misli na samopoškodovanje ali samomor.
A small number of people being treated with anti-epileptics such as Pregabalin Accord have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Pregabalin Accord, so se pojavile misli na samopoškodovanje ali samomor.
A small number of people being treated with anti-epileptics such as pregabalin have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je pregabalin, so se pojavile misli na samopoškodovanje ali samomor.
A small number of people being treated with anti-epileptics such as Pregabalin Mylan have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Pregabalin Mylan, so se pojavile misli na samopoškodovanje ali samomor.
A small number of people being treated with anti-epileptics such as Pregabalin Mylan Pharma have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Pregabalin Mylan Pharma, so se pojavile misli na samopoškodovanje ali samomor.
A small number of people being treated with anti-epileptics such as Pregabalin Pfizer have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Pregabalin Pfizer, so se pojavile misli na samopoškodovanje ali samomor.
A small number of people being treated with anti-epileptics such as Pregabalin Sandoz GmbH have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Pregabalin Sandoz GmbH, so se pojavile misli na samopoškodovanje ali samomor.
A small number of people being treated with anti-epileptics such as Pregabalin Sandoz have had thoughts of harming or killing themselves.
Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Pregabalin Sandoz, so se pojavile misli na samopoškodovanje ali samomor.
A small number of people being treated with antiepileptics such as Trobalt have had thoughts of harming or killing themselves.
Pri majhnem številu oseb, ki so dobivale zdravila proti epilepsiji, kakršno je zdravilo Trobalt, se je pojavilo razmišljanje o samopoškodovanju ali samomoru.
A small occasional impact on growth cannot be excluded upon vaccination on day-old ducklings free of maternally derived antibodies.
Pri cepljenju 1 dan starih mladičev brez maternalnih protiteles ni mogoče izključiti občasnega majhnega vpliva na rast živali.
A small pea size amount of gel should be applied to the forehead, chin, nose and each cheek, and then spread smoothly and evenly as a thin layer across the area.
Količino zdravila v velikosti grahovega zrna nanesite na čelo, brado, nos in vsako lice ter ga gladko, enakomerno in na tanko razmažite.
A small portion of gadofosveset dose was recovered in the faeces (4.7%, range 1.1 – 9.3%), indicating a minor role of biliary excretion in the disposition of gadofosveset.
Majhen del odmerka gadofosveseta se izloči v blatu (4,7 %, interval 1,1 - 9,3 %), kar nakazuje nepomembno vlogo izločanja gadofosveseta v žolču.
A small proportion of patients had prolonged peripheral B cell depletion lasting 2 years or more after their last dose of MabThera.
Pri majhnem deležu bolnikov je bil upad števila perifernih celic B dolgotrajen, trajal je 2 leti ali več po zadnjem odmerku zdravila MabThera.
A small rectangular area will be visible next to the oval display window.
Poleg ovalnega okenca za opazovanje zdravila se prikaže majhen štirioglati predel.
A small scale overdose (10x) study by spray is required and should be submitted by July 2015.
Opraviti je treba študijo v majhnem obsegu za prevelik odmerek (10x) z razpršilom in jo predložiti do julija 2015.
A small statistically significant increase in the PCE was observed in a pre-specified subgroup of patients with angina patients in CCS class II or higher at baseline (n=12049) (annual rates 3.4% versus 2.9%, relative risk ivabradine/placebo 1.18, p=0.018), but not in the subgroup of the overall angina population in CCS class ≥ I (n=14286) (relative risk ivabradine/placebo 1.11, p=0.110).
Majhno statistično značilno povečanje za primarni sestavljeni končni izid so opažali pri vnaprej določeni podskupini bolnikov z angino pektoris II. ali višjega razreda v izhodišču glede na oceno kanadskega srčno-žilnega združenja (CCS) (n = 12.049) (letna stopnja 3,4 % v primerjavi z 2,9%, relativno tveganje ivabradin : placebo 1,18, p = 0,018), vendar ne v podskupini skupne populacije bolnikov z angino pektoris iz razreda ≥ I (n = 14.286) (relativno tveganje ivabradin : placebo 1,11, p = 0,110) glede na oceno CCS.
A small transient swelling at the site of injection ( 4 cm), which can occasionally be firm and painful on palpation, has been observed very commonly in clinical studies.
Majhno prehodno oteklino na mestu injiciranja ( 4 cm), ki je včasih lahko trda in boleča na otip, so v kliničnih študijah opazili zelo pogosto.
A small volume is lost during preparation of PegIntron for injection when the dose is measured and injected.
Manjša količina raztopine se izgubi med pripravo zdravila PegIntron za injiciranje, ko odmerjate odmerek in ga injicirate.
A small volume is lost during preparation of ViraferonPeg for injection when the dose is measured and injected.
Manjša količina raztopine se izgubi med pripravo zdravila ViraferonPeg za injiciranje, ko odmerjate odmerek in ga injicirate.
A small, concentration dependent increase in QTc interval was observed in a phase I uncontrolled study.
V nenadzorovani študiji I. faze so opazili majhno, od koncentracije odvisno podaljšanje intervala QTc.
A small, concentration dependent increase in QTc interval was observed in an uncontrolled, open-label dose-escalation study of lapatinib in advanced cancer patients, such that an effect on QT interval cannot be ruled out.
V nekontrolirani, odprti študiji s povečevanjem odmerka pri bolnikih z napredovalim rakom so ugotovili majhno, od koncentracije odvisno podaljšanje QTc, tako da vpliva na interval QT ni mogoče izključiti.
A smaller proportion of patients treated with ibrutinib experienced a clinically meaningful worsening of lymphoma symptoms versus temsirolimus (27% versus 52%) and time to worsening of symptoms occurred more slowly with ibrutinib versus temsirolimus (HR 0.27, p < 0.0001).
Pri manjšem deležu bolnikov, zdravljenih z ibrutinibom je prišlo do klinično pomembnega poslabšanja simptomov limfoma v primerjavi s temsirolimusom (27% proti 52%), čas do poslabšanja simptomov pa je bil počasnejši pri ibrutinibu v primerjavi s temsirolimusom (HR 0,27, p < 0,0001).
A smaller supportive study was also carried out in adults.
Pri odraslih je bila opravljena tudi manjša podporna študija.
A solid performance status expressed as Body Mass Index (BMI) > 17 (to be assessed after drainage of ascites fluid) and Karnofsky Index > 60 is required prior to Removab therapy.
Pred začetkom zdravljenja z zdravilom Removab je potrebno oceniti status telesne zmogljivosti, izražen kot indeks telesne mase (BMI - Body Mass Index) (oceni se po drenaži ascitesa) in > 17 indeks po Karnofskem > 60.
A solution (stabiliser) is provided inside the BLINCYTO package and is used to coat the pre- filled infusion bag prior to addition of reconstituted BLINCYTO.
Pakiranju zdravila BLINCYTO je priložena raztopina (stabilizator), ki se uporablja za oblogo napolnjene infuzijske vrečke pred dodatkom rekonstituiranega zdravila BLINCYTO.
a sore mouth or lip, dry mouth, mouth ulcers or throat pain
vnetje ust ali ustnic, suha usta, razjede v ustih ali bolečine v grlu
a sound in one ear or both ears, such as buzzing, ringing or whistling;
zvoki v enem ali v obeh ušesih, kot so brenčanje, zvonenje ali žvižganje;
A special pack with patches of four different strengths is available to help when starting treatment for early-stage Parkinson’s disease.
Na začetku zdravljenja zgodnje faze Parkinsonove bolezni je bolnikom v pomoč poseben komplet z obliži štirih različnih jakosti.
A specialist doctor trained in hormone disorders must examine you to decide if it is safe to use Valtropin.
Zdravnik specialist, usposobljen za zdravljenje hormonskih motenj, vas mora pregledati in ugotoviti, ali je uporaba zdravila Valtropin varna.
A specific antidote antagonising the pharmacodynamic effect of rivaroxaban is not available.
Specifičnega antidota, ki bi izničil farmakodinamične učinke rivaroksabana, ni na voljo.
A specific controlled, 3-week trial has been conducted in patients suffering from major depressive disorder and insufficiently improved with paroxetine (a SSRI) or venlafaxine (a SNRI).
Bolniki z veliko depresivno epizodo, pri katerih zdravljenje s paroksetinom (SSRI) ali venlafaksinom (SNRI) ni pokazalo zadovoljivega izboljšanja, so bili vključeni v specifično kontrolno, 3-tedensko preskušanje.
A specific interaction study in healthy subjects revealed no influence of rufinamide at a dose of 400 mg bid on the pharmacokinetics of olanzapine, a CYP1A2 substrate.
Posebna študija interakcij pri zdravih osebah ni pokazala, da bi rufinamid v odmerku 400 mg dvakrat na dan vplival na farmakokinetiko olanzapina, ki je substrat CYP1A2.
A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient’s requirement are administered:
Specifičnega prevelikega odmerjanja insulina ni mogoče opredeliti, a če so uporabljeni odmerki preveliki glede na bolnikove potrebe, se lahko v zaporednih stopnjah razvije hipoglikemija:
A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient’s requirement are administered:
Specifičnega prevelikega odmerjanja insulina ni mogoče opredeliti, a če so uporabljeni odmerki preveliki glede na bolnikovo potrebo, se lahko postopoma razvije hipoglikemija.
A specific overdose for insulin cannot be defined; however, hypoglycaemia may develop over sequential stages if a patient is dosed with more insulin than required:
Specifičnega prevelikega odmerjanja insulina ni mogoče opredeliti, a če so uporabljeni odmerki preveliki glede na bolnikovo potrebo, se lahko postopoma razvije hipoglikemija.
A specific overdose of insulin cannot be defined.
Specificnega prevelikega odmerjanja insulina ni mogoce definirati.
A specific reversal agent (Praxbind®) is available (for details and more advice to reverse the anticoagulant effect of Pradaxa®, see Summary of Product Characteristics of Pradaxa® and Praxbind®).
Na voljo je specifična protiučinkovina (zdravilo Praxbind®) (podrobnejše informacije in priporočila, kako izničiti antikoagulacijski učinek zdravila Pradaxa®, boste našli v Povzetkih glavnih značilnosti zdravil Pradaxa® in Praxbind®).
A specific thorough QT/QTc study was conducted in healthy volunteers for definitive data demonstrating the effect of palonosetron on QT/QTc. (see section 5.1).
Pri zdravih prostovoljcih so opravili posebno temeljito študijo QT/QTc, da bi pridobili dokončne podatke, ki bi pokazali učinek palonosetrona na interval QT/QTc (glejte poglavje 5.1).
a spinning feeling (vertigo)
občutek vrtenja (vrtoglavica),
A spinning feeling in your head, making it difficult to stand up and move normally.
občutek vrtenja v glavi, zaradi katerega težko stojite in se normalno premikate,
A spinning feeling in your head, making it difficult to stand up and move normally.
vrtoglavica, težave pri stanju pokonci in normalnem premikanju,
A spoon is used to mix the content of the appropriate number of sachets (4 or 5 sachets depending on infant weight) with 10 ml of prepared liquid infant formula in the medicine cup or small container.
V merici za odmerjanje zdravil ali manjši posodici z žlico zmešajte vsebino ustreznega števila vrečic (4 ali 5 vrečic glede na telesno maso dojenčka) z 10 ml pripravljene začetne tekoče formule za dojenčke.
A spoon is used to mix the content of the sachets with 30 ml of the beverage.
Z žlico zmešajte vsebino vrečic s 30 ml napitka.
A spray is then administered by pressing and releasing the finger grips either side of the nozzle.
Nato aplicira vpih tako, da pritisne na sprožilec in ga spusti.
A stable response was observed in an additional 10/35 patients (28.6%).
Stabilen odziv je bil opaţen pri dodatnih 10/35 bolnikov (28,6 %).
A standard scale, known as the ‘knee injury and osteoarthritis outcome score’ (KOOS), was used to measure pain and knee function, where 0 reflects extreme problems and 100 reflects an absence of problems.
Za merjenje bolečine in funkcije kolena je bila uporabljena standardna lestvica KOOS (merjenje izida ob poškodbi kolena in osteoartritisu), pri čemer 0 odraža izjemne težave, 100 pa odsotnost težav.
A starting dose is set by your doctor.
Začetni odmerek določi zdravnik.
A starting dose of 18.5 mg is recommended and the maximum dose of lurasidone should not exceed 74 mg once daily in combination with moderate CYP3A4 inhibitors.
Priporočeni začetni odmerek v kombinaciji z zmernimi zaviralci CYP3A4 je 18,5 mg, največji odmerek lurasidona pa v takšni kombinaciji ne sme preseči 74 mg enkrat na dan.
A starting dose of 200 mg (the contents of 4 pre-filled pens) followed by 100 mg (the contents of 2 pre-filled pens) 2 weeks later.
Začetni odmerek 200 mg (vsebina 4 napolnjenih injekcijskih peresnikov), ki mu sledi 100 mg (vsebina 2 napolnjenih injekcijskih peresnikov) 2 tedna kasneje.
A starting dose of 24 mg/26 mg twice daily should be considered in patients with moderate renal impairment (eGFR 30-60 ml/min/1.73 m2).
Pri bolnikih z zmerno okvaro ledvic (z ocenjeno hitrostjo glomerulne filtracije 30-60 ml/min/1,73 m2) je treba razmisliti o začetnem odmerku 24 mg/26 mg dvakrat na dan.
A starting dose of 4 to 6 g per day can be used in patients who need urgent control of Cushing’s syndrome (a set of symptoms of adrenal gland cancer caused by high hormone levels).
Pri bolnikih, ki potrebujejo nujni nadzor nad Cushingovim sindromom (skupek simptomov, ki se pojavijo pri raku nadledvične žleze in jih povzročajo visoke ravni hormonov), lahko začetni dnevni odmerek znaša 4 do 6 g.
A starting dose of 5 mg should be considered in patients with mild and moderate hepatic impairment (Child-Pugh A-B).
Začetni odmerek za bolnike z blago in zmerno jetrno okvaro (Child-Pugh A-B) je 5 mg.
A starting dose of Relvar Ellipta 92/22 micrograms should be considered for adults and adolescents 12 years and over who require a low to mid dose of inhaled corticosteroid in combination with a long-acting beta2- agonist.
Za odrasle in mladostnike v starosti 12 let ali več, ki potrebujejo nizek do srednji odmerek inhaliranega kortikosteroida v kombinaciji z dolgodelujočim agonistom adrenergičnih receptorjev beta2, pride v poštev začetni odmerek zdravila Relvar Ellipta 92/22 mikrogramov.
A starting dose of Revinty Ellipta 92/22 micrograms should be considered for adults and adolescents 12 years and over who require a low to mid dose of inhaled corticosteroid in combination with a long-acting beta2-agonist.
Za odrasle in mladostnike v starosti 12 let ali več, ki potrebujejo nizek do srednji odmerek inhaliranega kortikosteroida v kombinaciji z dolgodelujočim agonistom adrenergičnih receptorjev beta2, pride v poštev začetni odmerek zdravila Revinty Ellipta 92/22 mikrogramov.